Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
What is GenFleet Therapeutics (Shanghai) Days Payable?
GenFleet Therapeutics (Shanghai)HAM:Y3L -2.80%19 Days Payable is 161.16 as of Dec. 2025, which is 19% above its 10-year median of 134.89. GuruFocus rates HAM:Y3L with a GF Score™ of 19/100. The stock has 3 warning signs investors should review. Among 703 Biotechnology companies, GenFleet Therapeutics (Shanghai) ranks better than 57.61% on this metric.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
GenFleet Therapeutics (Shanghai) Days Payable Chart
GenFleet Therapeutics (Shanghai) Annual Data
Trend
Dec23
Dec24
Dec25
Days Payable
4,501.67
131.41
121.14
GenFleet Therapeutics (Shanghai) Semi-Annual Data
Dec23
Jun24
Dec24
Jun25
Dec25
Days Payable
0.00
0.00
57.12
190.14
161.16
HAM:Y3L vs VRTX, REGN, RVMD: Days Payable Comparison
For the Biotechnology subindustry, GenFleet Therapeutics (Shanghai)'s Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
GenFleet Therapeutics (Shanghai) Days Payable vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, GenFleet Therapeutics (Shanghai)'s Days Payable distribution charts can be found below:
* The bar in red indicates where GenFleet Therapeutics (Shanghai)'s Days Payable falls into.
GenFleet Therapeutics (Shanghai) Days Payable Calculation
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
GenFleet Therapeutics (Shanghai) (HAM:Y3L) has a Days Payable of 161.16 as of Dec. 2025. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on GenFleet Therapeutics (Shanghai) and its competitors. This is 19% above median its historical median of 134.89. Over the past decade, GenFleet Therapeutics (Shanghai)'s Days Payable has ranged from 118.28 to 4,459.54. According to the industry distribution chart, GenFleet Therapeutics (Shanghai) ranks #298 out of 703 companies in the Biotechnology industry, placing it in the top 42.4%.
Is GenFleet Therapeutics (Shanghai)'s Days Payable too high?
GenFleet Therapeutics (Shanghai)'s current Days Payable of 161.16 is 19% above median its 10-year median of 134.89. Over the past 10 years, this metric has ranged from a low of 118.28 to a high of 4,459.54. The Biotechnology industry median Days Payable is 112.84. GenFleet Therapeutics (Shanghai)'s value of 161.16 is 42.8% above this industry median. Based on the distribution chart, GenFleet Therapeutics (Shanghai) ranks #298 out of 703 companies in the Biotechnology industry, which is above the industry midpoint. Overall, GenFleet Therapeutics (Shanghai) has a GF Score™ of 19/100, reflecting its overall financial health beyond just this single metric.
How does GenFleet Therapeutics (Shanghai)'s Days Payable compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, GenFleet Therapeutics (Shanghai) ranks #298 out of 703 companies for Days Payable. This puts GenFleet Therapeutics (Shanghai) in the upper half of its industry. The industry median Days Payable is 112.84. GenFleet Therapeutics (Shanghai)'s value of 161.16 is 42.8% above this benchmark. Historically, GenFleet Therapeutics (Shanghai)'s own Days Payable has ranged from 118.28 to 4,459.54 over the past decade. While the company's 10-year median is 134.89 vs. the industry median of 112.84, GenFleet Therapeutics (Shanghai) has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Biotechnology company?
The median Days Payable among Biotechnology companies is 112.84, based on 703 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. GenFleet Therapeutics (Shanghai)'s current Days Payable of 161.16 is 42.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on GenFleet Therapeutics (Shanghai) and its competitors. For the Biotechnology industry, the median Days Payable is 112.84 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. GenFleet Therapeutics (Shanghai)'s current Days Payable is 161.16, which is 19% above median its own 10-year median of 134.89. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is GenFleet Therapeutics (Shanghai) stock overvalued right now?
GenFleet Therapeutics (Shanghai) (HAM:Y3L) has a current Days Payable of 161.16. The current Days Payable is 161.16, which is 19% above median its 10-year median of 134.89 and 42.8% above the Biotechnology industry median of 112.84. GenFleet Therapeutics (Shanghai)'s overall GF Score™ is 19/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For GenFleet Therapeutics (Shanghai) (HAM:Y3L), the current Days Payable is 161.16 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
GenFleet Therapeutics (Shanghai) Inc Company is a clinical-stage biotechnology company. The Company and its subsidiaries are principally engaged in the research, development and commercialisation of pharmaceutical products. The Group is engaged in biopharmaceutical research and development, which is regarded as a single reportable segment.
19GF Score
Get the complete analysis for HAM:Y3L
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HAM:Y3L has been successfully added to your 
